68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
Terminated
National Cancer Institute (NCI)
Early Phase 1
2017-05-16
This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission
tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine
tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic
procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
Terminated
M.D. Anderson Cancer Center
Early Phase 1
2017-05-16
This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission
tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine
tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic
procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
This preview shows a limited data set Subscribe for full access, or try a Trial
Last updated: May 19, 2026
Gallium Ga 68 Edotreotide Clinical Trials Update, Market Analysis, and Forecast (2026-2035)
Executive summary: Public disclosures support continued clinical and market interest in Ga 68 edotreotide (somatostatin receptor imaging; SSTR2-targeted). The commercial outlook depends on: (1) availability of GMP supply for radiopharmaceutical generator systems, (2) payer and site adoption of SSTR-PET pathways versus alternative tracers (e.g., Ga 68 dotatate), and (3) competition from branded and generic-equivalent radiopharmaceuticals in the US and EU. A forecast cannot be completed to an actionable numeric level without verifiable, source-backed inputs (trial status endpoints, dosing volume assumptions, pricing, and reimbursement).
No complete, source-anchored basis is available to produce a complete and accurate clinical-trials update and a quantified market projection within the constraints.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
